-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] According to industry statistics, in March 2022, 86 new varieties have passed/deemed to pass the consistency evaluation, involving 92 enterprises
.
Among them, 15 varieties are the first to review
.
From the point of view of over-evaluated companies, Chengdu Bite has performed particularly well.
In March, 5 varieties have passed the consistency evaluation, including salbutamol desulfate injection, dexamethasone sodium phosphate injection, lidocaine hydrochloride injection, Laxole sustained-release tablets,
etc.
Not long ago, Chengdu Beite was the first company in China to regard the salbutamol sulfate injection as a copy of Class 3 production
.
According to data from Minet.
com, the market size of terminal salbutamol in China's public medical institutions has exceeded 1 billion yuan in 2020, of which injection sales accounted for about 21%
.
In addition, 5 companies including North China Pharmaceutical, Yichang East Sunshine, Yangzijiang, Hengrui, and Nord Pharmaceutical have reviewed 3 varieties; 4 companies including Tianfang Pharmaceutical, Jinyao Pharmaceutical, Yuekang Pharmaceutical, and Chia Tai Tianqing There are 2 varieties of pharmaceutical companies over-reviewed
.
Judging from the 86 varieties that have been reviewed, the varieties that have been reviewed by many pharmaceutical companies are the same variety
.
For example, levofloxacin sodium chloride injection, ticagrelor tablets, cefepime hydrochloride for injection, etc.
, these varieties were reviewed by 3 companies in March; edaravone injection, clarithromycin tablets and other varieties have 2 companies have been reviewed
.
Among them, ticagrelor tablets have been reviewed by 25 companies
.
It is worth mentioning that there are many large varieties that these pharmaceutical companies have gathered and reviewed
.
For example, levofloxacin sodium chloride injection, which belongs to the quinolone antibiotics, is suitable for respiratory system infections, urinary system infections, reproductive system infections, skin and soft tissue infections, intestinal infections, sepsis and other infections caused by sensitive bacteria
.
According to data from Minet.
com, the sales of levofloxacin injection in public medical institutions in China will exceed 4.
6 billion yuan in 2020
.
In addition, in the first half of 2021, the sales of this product have exceeded 2 billion yuan, a year-on-year increase of 4.
58%
.
Up to now, more than 10 pharmaceutical companies have passed the consistency evaluation of this product
.
Edaravone injection is a cerebral protective agent (free radical scavenger), used to improve neurological symptoms, activities of daily living and dysfunction caused by acute cerebral infarction, and to inhibit amyotrophic lateral sclerosis (ALS).
Progression of dysfunction
.
According to data from IQVIA and Minet, the domestic market size of edaravone injection in 2020 is approximately RMB 1.
07 billion (calculated at the tender price)
.
Up to now, the companies that have reviewed this product include Shandong Luoxin Pharmaceutical, Fujian Tianquan Pharmaceutical, Hebei Renhe Yikang Pharmaceutical, Guorui Pharmaceutical, Yangzijiang, Qilu Pharmaceutical, Boda Pharmaceutical,
etc.
Another example is clarithromycin tablets, which are macrolide antibiotics commonly used in clinical practice and are suitable for the treatment of infections caused by pathogenic bacteria sensitive to clarithromycin
.
Data shows that at present, the sales of clarithromycin tablets in Chinese public medical institutions and physical pharmacy terminals in Chinese cities are also approaching 1 billion yuan
.
So far, clarithromycin tablets have been reviewed by more than 10 companies, including Livzon Group, Sunshine Pharmaceuticals, CSPC, Yiling Pharmaceuticals, and Modern Pharmaceuticals
.
According to relevant national policies, drug varieties that have passed the consistency evaluation will receive greater support in the fields of medical insurance payment and procurement by medical institutions
.
In general, in the context of fierce competition in the pharmaceutical market, with the advancement of generic drug consistency evaluation, consistency evaluation has become a battle of the strong
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, 15 varieties are the first to review
.
From the point of view of over-evaluated companies, Chengdu Bite has performed particularly well.
In March, 5 varieties have passed the consistency evaluation, including salbutamol desulfate injection, dexamethasone sodium phosphate injection, lidocaine hydrochloride injection, Laxole sustained-release tablets,
etc.
Not long ago, Chengdu Beite was the first company in China to regard the salbutamol sulfate injection as a copy of Class 3 production
.
According to data from Minet.
com, the market size of terminal salbutamol in China's public medical institutions has exceeded 1 billion yuan in 2020, of which injection sales accounted for about 21%
.
In addition, 5 companies including North China Pharmaceutical, Yichang East Sunshine, Yangzijiang, Hengrui, and Nord Pharmaceutical have reviewed 3 varieties; 4 companies including Tianfang Pharmaceutical, Jinyao Pharmaceutical, Yuekang Pharmaceutical, and Chia Tai Tianqing There are 2 varieties of pharmaceutical companies over-reviewed
.
Judging from the 86 varieties that have been reviewed, the varieties that have been reviewed by many pharmaceutical companies are the same variety
.
For example, levofloxacin sodium chloride injection, ticagrelor tablets, cefepime hydrochloride for injection, etc.
, these varieties were reviewed by 3 companies in March; edaravone injection, clarithromycin tablets and other varieties have 2 companies have been reviewed
.
Among them, ticagrelor tablets have been reviewed by 25 companies
.
It is worth mentioning that there are many large varieties that these pharmaceutical companies have gathered and reviewed
.
For example, levofloxacin sodium chloride injection, which belongs to the quinolone antibiotics, is suitable for respiratory system infections, urinary system infections, reproductive system infections, skin and soft tissue infections, intestinal infections, sepsis and other infections caused by sensitive bacteria
.
According to data from Minet.
com, the sales of levofloxacin injection in public medical institutions in China will exceed 4.
6 billion yuan in 2020
.
In addition, in the first half of 2021, the sales of this product have exceeded 2 billion yuan, a year-on-year increase of 4.
58%
.
Up to now, more than 10 pharmaceutical companies have passed the consistency evaluation of this product
.
Edaravone injection is a cerebral protective agent (free radical scavenger), used to improve neurological symptoms, activities of daily living and dysfunction caused by acute cerebral infarction, and to inhibit amyotrophic lateral sclerosis (ALS).
Progression of dysfunction
.
According to data from IQVIA and Minet, the domestic market size of edaravone injection in 2020 is approximately RMB 1.
07 billion (calculated at the tender price)
.
Up to now, the companies that have reviewed this product include Shandong Luoxin Pharmaceutical, Fujian Tianquan Pharmaceutical, Hebei Renhe Yikang Pharmaceutical, Guorui Pharmaceutical, Yangzijiang, Qilu Pharmaceutical, Boda Pharmaceutical,
etc.
Another example is clarithromycin tablets, which are macrolide antibiotics commonly used in clinical practice and are suitable for the treatment of infections caused by pathogenic bacteria sensitive to clarithromycin
.
Data shows that at present, the sales of clarithromycin tablets in Chinese public medical institutions and physical pharmacy terminals in Chinese cities are also approaching 1 billion yuan
.
So far, clarithromycin tablets have been reviewed by more than 10 companies, including Livzon Group, Sunshine Pharmaceuticals, CSPC, Yiling Pharmaceuticals, and Modern Pharmaceuticals
.
According to relevant national policies, drug varieties that have passed the consistency evaluation will receive greater support in the fields of medical insurance payment and procurement by medical institutions
.
In general, in the context of fierce competition in the pharmaceutical market, with the advancement of generic drug consistency evaluation, consistency evaluation has become a battle of the strong
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
